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Congenital long QT syndrome (LQTS) is an inherited
cardiac channelopathy characterized by prolongation of the
QT interval on electrocardiogram (ECG), and is associated
with an increased risk of life-threatening ventricular arrhyth-
mias. Mutations in over a dozen distinct genes have been
implicated in the pathogenesis of this group of disorders.1
LQTS type 1 (LQT1), the most prevalent LQTS subtype, is
characterized by a heterozygous loss-of-function mutation in
the KCNQ1 gene, which codes for the α-subunit of the
delayed rectiﬁer inward potassium ion channel. The associ-
ation of LQTS with dilated cardiomyopathy (DCM) is rare
but has been reported in the presence of sodium channel gene
mutations, as seen in LQTS type 3. In this case report, we
describe a patient with familial LQT1 (KCNQ1 mutation)
identiﬁed in infancy who was subsequently diagnosed with
severe DCM later in childhood.
Case report
A 2-day-old male infant underwent cardiology evaluation
owing to a family history of LQTS. Evaluation of the
extended family had previously been remarkable for multiple
family members, including his mother, having a prolonged
QTc on ECG screening. The patient’s ECG demonstrated a
QTc of 495 msec and abnormal T-wave morphology
(Figure 1A). He was admitted to the hospital for initiation
of propranolol. Genetic testing of the patient and multiple
ﬁrst- and second-degree maternal relatives identiﬁed the
presence of a deleterious genetic mutation, KCNQ1 Ser 349
Ter, consistent with LQT1. The patient’s older brother, who
had previously been thought to be unaffected, was also found
to be positive for the mutation and started on medication. The
patient was maintained on propranolol until 4 years of age,KEYWORDS Familial long QT syndrome; Dilated cardiomyopathy; KCNQ1;
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).and nadolol thereafter. Throughout this time he was clin-
ically well, without palpitations, syncope, or documented
arrhythmias, although his QTc remained prolonged on serial
ECG evaluations. He underwent formal exercise testing at 7
years of age, which was notable for a prolonged QTc
throughout exercise and recovery. There were no arrhyth-
mias and he had a normal oxygen consumption of 40.5 mL/
kg/min. He was active in multiple recreational sports,
including basketball, lacrosse, and baseball; an automated
external deﬁbrillator was available for emergency use.
Repeat exercise testing was performed at 8 years of age,
which again demonstrated a prolonged QTc without ven-
tricular ectopy. Oxygen consumption was not measured, but
his physical working capacity was described as low (work
rate 67 watts).
At 9 years of age, the patient was admitted to the hospital
complaining of several days of diffuse abdominal pain,
vomiting, diarrhea, and fatigue. He was admitted to the
general pediatric service with a presumed diagnosis of viral
gastroenteritis and discharged home the following day after
receiving intravenous hydration. He presented to the emer-
gency room 1 week later with continued gastrointestinal
symptoms, as well as worsening fatigue and dyspnea. The
initial physical examination was notable for tachypnea and
intermittent retractions. On auscultation, a 1/6 holosystolic
murmur was heard at the apex, with no other abnormalities.
Hepatomegaly with tenderness to palpation was present. The
initial laboratory evaluation was notable for an elevated
B-type natriuretic peptide of 8578 pg/mL. A chest radio-
graph showed increased interstitial markings without pulmo-
nary edema or cardiomegaly. His ECG showed new T wave
changes and voltage criteria for left ventricular (LV) hyper-
trophy, but no evidence of arrhythmia (Figure 1B). A
transthoracic echocardiogram was performed and demon-
strated severely diminished LV ejection with a markedly
dilated left atrium, a mildly dilated left ventricle, and
moderate to severe mitral regurgitation. The LV ejection
fraction (EF), as estimated by Simpson’s rule (biplane), was
15%. Right ventricular (RV) ejection was decreased as well,
but not as markedly as that of the left ventricle. There waspen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 An association between long QT syndrome and
dilated cardiomyopathy has been previously
described in the presence of SCN5A mutations and
may represent a sodium channel “overlap
syndrome” between channelopathies and
cardiomyopathies.
 It is possible that molecular interaction between
potassium channel mutations and other mutations
in the cardiac sarcomere and mitochondria may
lead to a phenotypic overlap syndrome between
long QT syndrome and cardiomyopathy.
 Additional screening for cardiomyopathy may be
warranted in patients with a variety of genetic
channelopathies.
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pressures with an RV pressure estimate of 38 mm Hg above
central venous pressure and a pulmonary artery end-diastolic
pressure estimated at 15 mmHg using the modiﬁed Bernoulli
equation (Figure 2). An infectious evaluation failed to show
any evidence of active viral infection (blood polymeraseFigure 1 A: Twelve-lead electrocardiogram obtained at 2 days of life showing a
Twelve-lead electrocardiogram obtained at time of presentation with heart failure at
ventricular hypertrophy.chain reaction assays for adenovirus, inﬂuenza, parainﬂuenza,
metapneumovirus, rhinovirus, enterovirus, cytomegalovirus,
HHV-6, parechovirus, parvovirus B19, Epstein-Barr virus,
and stool polymerase chain reaction assays for common
gastrointestinal pathogens were all negative) or systemic
inﬂammation (C-reactive protein o0.5 mg/dL, erythrocyte
sedimentation rate 0 mm/h) and the troponin I was 0.01 ng/
mL. He was treated with 2 g/kg of intravenous immunoglo-
bulin, without improvement.
A metabolic evaluation (lactate, pyruvate, acylcarnitine
proﬁle, blood and urine carnitine levels, plasma amino acids,
urine organic acid, and creatine kinase) was negative. Com-
mercial genetic testing consisting of DNA sequencing for 51
known cardiomyopathy genes was performed by the Labora-
tory for Molecular Medicine (Boston, MA) and was notable
for a variant of unknown signiﬁcance in the titin gene
(p.Asn18096Lys). A Combined Mito Genome Plus Mito 140
Nuclear Gene Panel (GeneDx, Gaithersburg, MD) was also
performed and showed heterozygosity for a variant of unknown
signiﬁcance in the ACO2 gene (p.Arg142Gln) and hetero-
zygosity for a variant of unknown signiﬁcance in the
NDUFA10 gene (p.Arg337His). Cardiac magnetic resonance
imaging (MRI) was obtained and demonstrated moderate to
severe LV dilation (end-diastolic volume 165 mL/m2), severely
diminished LV ejection (EF 21%), and moderately diminishedcorrected QT interval of 495 msec and nonspeciﬁc T wave abnormalities. B:
9 years of age demonstrating new T wave changes and voltage criteria for left
Figure 2 Transthoracic echocardiogram showing severe dilation and systolic dysfunction of the left ventricle.
Heart Rhythm Case Reports, Vol 2, No 2, March 2016130RV ejection (EF 32%) without dilation or hypertrophy. MRI
tissue characterization was limited owing to myocardial thin-
ning, but the Lake Louise criteria for MRI diagnosis of
myocarditis were not met.2 Based on these ﬁndings, a diagnosis
of idiopathic DCM was made. Upon clinical improvement,
milrinone was discontinued and he was transitioned to an oral
regimen of enalapril, digoxin, nadolol, and enteral diuretics.
Owing to his lack of arrhythmias and relative small size,
placement of a primary prevention implantable cardioverter-
deﬁbrillator was deferred. He was discharged home after
approximately 4 weeks, but required readmission for reinitia-
tion of milrinone approximately 1 month later owing to
recurrent symptoms of congestive heart failure. A cardiac
catheterization was performed during that admission and was
notable for preserved cardiac index of 3.6 L/min/m2 (on
milrinone), elevated pulmonary capillary wedge pressure ofFigure 3 Family pedigree demonstrating mutations in the KCNQ1 and titin ge
degree relatives were affected, including a maternal cousin with sudden cardiac dea
the KCNQ1 gene was identiﬁed.14 mm Hg, and normal pulmonary vascular resistance. Based
on these ﬁndings and clinical status, the patient was listed for
heart transplantation. He recently underwent an uncomplicated
orthotopic heart transplant. Gross pathologic examination of the
explanted heart was consistent with the diagnosis of DCM, with
scattered myocyte hypertrophy on microscopic examination.
The patient’s older brother, who also has the LQT1mutation,
was evaluated with screening echocardiography and has normal
cardiac chamber size and systolic function. No other family
members have been diagnosed with cardiomyopathy (Figure 3).Discussion
To our knowledge, this is the ﬁrst report in the medical
literature of an association between LQT1 and DCM. Our
patient is unique, as he carries genotypic and phenotypicnes. The KCNQ1 was inherited maternally and multiple ﬁrst- and second-
th. The titin gene mutation was inherited paternally and no other overlap with
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without evidence of frequent ventricular ectopic beats or
sustained arrhythmias, making a tachycardia- or PVC-
induced cardiomyopathy unlikely. His inﬂammatory
markers and infectious evaluation were negative, and cardiac
MRI did not show convincing evidence of myocarditis;
therefore, a concurrent myocarditis is highly unlikely. Our
patient’s presentation, therefore, is more consistent with an
idiopathic DCM of subacute onset.
While a cardiac sodium channel “overlap syndrome”
between channelopathies and cardiomyopathies has been
described related to abnormalities in the SCN5A gene, no
such association with DCM has been described with respect
to the cardiac potassium channels involved in LQT1. The
SCN5A gene encodes the α-subunit of the voltage-
dependent cardiac sodium channel and has been implicated
in a number of pathologic cardiac conditions, including
LQTS type 3 (LQT3), Brugada syndrome, sick sinus
syndrome, conduction system disease, sudden infant death
syndrome, and DCM. A study by McNair et al3 found an
SCN5A mutation prevalence of 1.7% in their multicenter
cohort of 338 patients with DCM. While none of these
patients had QTc prolongation, multiple case reports have
described an overlap between ECG evidence of LQTS andDCM
in patients withmutations in the SCN5Agene.4,5 Themechanism
of overlap between channelopathy and cardiomyopathy in LQT3
is not well understood, but it has been proposed that ion channel
mutations may ultimately result in structural changes to the
myocardial tissue via their interaction with cytoskeletal proteins,
either directly or as a result of altered ion homeostasis.6,7 KCNQ1
gene mutations have not previously been described in patients
with DCM, but they have been implicated in other types of
cardiomyopathies such as hypertrophic cardiomyopathy and LV
noncompaction cardiomyopathy.8,9 The delayed rectiﬁer potas-
sium channel affected in LQT1 is one of several types of
potassium channels responsible for reconstitution of the cardiac
action potential, whereas the function of the SCN5A channel is
absolutely necessary for depolarization and, hence, contractile
function.10,11 It may be that, unlike sodium channel mutations, a
single potassium channel mutation is insufﬁcient to cause a
signiﬁcant effect on contractile function without additional
abnormalities in cytoskeletal proteins or cardiac metabolism.
Genetic testing of known cardiomyopathy genes revealed
genetic variants of unknown signiﬁcance in mitochondrial
genes involved in the electron transport chain and in titin, an
autosomal gene coding for a sarcomere protein commonly
implicated in DCM. It is possible that normally nonpatho-
genic variations in the titin gene can become disease-
producing via interaction with mutations in other susceptible
genes.12 It has been previously suggested that titin may
inﬂuence activity of the delayed outward rectifying potas-
sium currents affected in LQT1.13 While the KCNQ1
mutation was inherited maternally, the titin mutation was
inherited paternally, and overlap between the KCNQ1 and
titin mutations was not identiﬁed in any other maternal
family member (Figure 3).Conclusions
While a mutation in KCNQ1 has not been previously
described as an etiology for DCM, we hypothesize that the
potassium ion channel could be involved in the pathogenesis
of myocardial dilation and resultant ventricular dysfunction,
either in isolation or via molecular interplay with other
genetic variants of unknown signiﬁcance. Similar to SCN5A,
it is possible that a potassium channel overlap syndrome may
exist. There has been little investigation into the role of the
delayed rectiﬁer potassium channel in heart failure.14 More
research is needed into the possible pathogenic manifesta-
tions of this mutation within the cardiac myocyte. From a
clinical standpoint, patients with known deleterious potas-
sium and sodium channel genetic mutations should be
carefully monitored for both QTc prolongation and ventric-
ular dysfunction, irrespective of the presenting phenotype.Appendix
Supplementary data
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.hrcr.2015.10.011.References
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